Beck Mack & Oliver LLC continued to hold its stake in Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 12,100 shares of the medical research company’s stock at the end of the third quarter. Beck Mack & Oliver LLC’s holdings in Amgen were worth $2,018,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of AMGN. Integrated Wealth Management boosted its position in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares during the last quarter. Goelzer Investment Management Inc. boosted its position in shares of Amgen by 0.3% in the second quarter. Goelzer Investment Management Inc. now owns 1,604 shares of the medical research company’s stock worth $244,000 after buying an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC boosted its position in shares of Amgen by 0.5% in the third quarter. Capital Advisors Ltd. LLC now owns 1,083 shares of the medical research company’s stock worth $181,000 after buying an additional 5 shares during the last quarter. Nadler Financial Group Inc. boosted its position in shares of Amgen by 0.3% in the second quarter. Nadler Financial Group Inc. now owns 2,111 shares of the medical research company’s stock worth $321,000 after buying an additional 6 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its position in shares of Amgen by 0.4% in the second quarter. Parkside Financial Bank & Trust now owns 1,463 shares of the medical research company’s stock worth $223,000 after buying an additional 6 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded up 0.64% during midday trading on Tuesday, reaching $146.00. The company’s stock had a trading volume of 2,939,137 shares. The stock has a market capitalization of $108.61 billion, a price-to-earnings ratio of 14.61 and a beta of 1.15. The firm has a 50-day moving average price of $151.01 and a 200 day moving average price of $160.49. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $176.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.23. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.73 billion. During the same quarter last year, the firm posted $2.72 earnings per share. The business’s revenue was up 1.5% compared to the same quarter last year. Equities research analysts predict that Amgen Inc. will post $11.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Shareholders of record on Wednesday, November 16th will be paid a $1.00 dividend. The ex-dividend date of this dividend is Monday, November 14th. This represents a $4.00 dividend on an annualized basis and a yield of 2.74%. Amgen’s payout ratio is 39.92%.

WARNING: This article was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/11/29/beck-mack-oliver-llc-has-2018000-position-in-amgen-inc-amgn.html.

A number of research analysts recently weighed in on the company. Leerink Swann set a $163.00 target price on Amgen and gave the company a “hold” rating in a report on Monday, November 21st. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $167.77 target price on the stock. in a report on Thursday, November 10th. Mizuho assumed coverage on Amgen in a report on Monday, November 7th. They issued a “buy” rating and a $164.00 target price on the stock. RBC Capital Markets set a $190.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Sunday, October 30th. Finally, Jefferies Group restated a “buy” rating on shares of Amgen in a research note on Wednesday, September 28th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $182.04.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.